ArticleCancers2022

MAEL Augments Cancer Stemness Properties and Resistance to Sorafenib in Hepatocellular Carcinoma through the PTGS2/AKT/STAT3 Axis.

Chaoran Shi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.